Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.69 |
| ▸ | ITGAV | P06756 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.64 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | DDX3X | O00571 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893846 | 0.87 | KMT2A (0.55) | ITGB3ITGAVKMT2AMEN1ITGB1 | |
| SCHEMBL7443824 | 0.85 | ITGB3 (0.71) | ITGB3ITGAVKMT2AMEN1ITGB1 | |
| SCHEMBL4893227 | 0.82 | POLB (0.72) | ITGB3ITGAVKMT2AMEN1GAA | |
| SCHEMBL17084270 | 0.82 | KMT2A (0.69) | ITGB3ITGAVKMT2AMEN1ITGB1 | |
| SCHEMBL4904022 | 0.81 | POLB (0.51) | ITGB3ITGAVKMT2AMEN1RAB9A | |
| SCHEMBL11911371 | 0.81 | ITGB3 (0.70) | ITGB3ITGAVKMT2AMEN1ITGB1 | |
| SCHEMBL17079633 | 0.81 | ITGB3 (0.66) | ITGB3ITGAVKMT2AMEN1ITGB1 | |
| SCHEMBL4893345 | 0.80 | HTT (0.58) | ITGB3ITGAVKMT2AMEN1GAA | |
| SCHEMBL1275926 | 0.80 | RAB9A (0.75) | ITGB3ITGAVKMT2AMEN1ITGB1 | |
| SCHEMBL17079630 | 0.80 | KMT2A (0.70) | ITGB3ITGAVKMT2AMEN1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2C, ADRA2A | ITGB3 1700/4885ITGAV 1185/4885KMT2A 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.